RNAC News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

RN

Mkt Cap

$189.4M

Volume

92.21K

Next Earnings

November 5th

Loading chart

RN

RNACCartesian Therapeutics, Inc. Common Stock

RNAC

Pay with—

Available Balance0.00

RN

Mkt Cap

$189.7M

Volume

92.21K

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

Myasthenia Gravis Clinical Trial Pipeline Expands as 25+ Companies Race to Redefine Myasthenia Gravis Treatment Landscape | DelveInsightOver 25 pharmaceutical companies are advancing 30+ pipeline drugs for myasthenia gravis treatment, with approximately 5+ therapies in late-stage development. Key players including Immunovant, Cartesian Therapeutics, Novartis, and others are developing promising therapies using novel mechanisms of action such as IgG degraders and complement inhibitors. Recent developments include positive Phase III trial results and regulatory approvals for multiple candidates.GlobeNewswire Inc. · Jun 2, 2026

Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027Cartesian Therapeutics secured up to $150 million in non-dilutive financing from K2 HealthVentures, with an initial $50 million tranche extending cash runway into 2028. The company expects Phase 3 AURORA trial topline data for Descartes-08 in myasthenia gravis in Q1 2027, with BLA filing planned for mid-2027. Additional clinical data from Phase 2 TRITON (myositis) and Phase 1/2 HELIOS (juvenile dermatomyositis) trials are expected in H1 2027.GlobeNewswire Inc. · May 26, 2026

Myasthenia Gravis Market Set to Surpass USD 16 Billion by 2036, Fueled by Rising Diagnosed Prevalence and Wave of Targeted Biologic Approvals | DelveInsightThe myasthenia gravis market is projected to grow from USD 6 billion in 2025 to over USD 16 billion by 2036, driven by rising diagnosed prevalence, improved diagnostics, and an expanding pipeline of targeted biologic therapies including FcRn inhibitors, complement inhibitors, and CAR-T cell therapies. The market is currently led by argenx and UCB, with numerous emerging candidates in late-stage development expected to significantly accelerate growth.GlobeNewswire Inc. · May 18, 2026

Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQCartesian Therapeutics announced its participation in the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026. The company, a late clinical-stage biotech firm, is advancing its lead asset Descartes-08, a CAR-T cell therapy in Phase 3 development for generalized myasthenia gravis and Phase 2 for myositis, with Phase 1/2 trials underway for pediatric autoimmune diseases.GlobeNewswire Inc. · May 12, 2026

Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsightThe generalized myasthenia gravis (gMG) market is experiencing significant growth with 8 promising late-stage drug candidates in development. The gMG market across 7 major markets was valued at USD 5.9 billion in 2025 and is projected to grow at 9.1% CAGR through 2036. Key therapies in development include FcRn inhibitors, complement inhibitors, BTK inhibitors, and innovative CAR-T cell therapies from major pharmaceutical companies.GlobeNewswire Inc. · Apr 15, 2026

Generalized Myasthenia Gravis Market Outlook Shows Strong Momentum During the Forecast Period (2025–2034) Driven by Novel Immunotherapies | DelveInsightThe generalized myasthenia gravis (gMG) market is expected to grow significantly through 2034, driven by novel immunotherapies including FABHALTA (iptacopan) from Novartis, Descartes-08 from Cartesian Therapeutics, and Claseprubart from Dianthus Therapeutics. The 7MM had approximately 205,000 prevalent gMG cases in 2024, with increasing incidence projected. These emerging therapies represent a shift toward mechanism-driven treatments targeting refractory disease and improving long-term disease control.GlobeNewswire Inc. · Jan 14, 2026

Johnson & Johnson Touts Encouraging Results For Experimental Lupus TreatmentJohnson & Johnson announced positive Phase 2b results for nipocalimab, an experimental FcRn blocker for treating systemic lupus erythematosus (SLE). The JASMINE study of 228 subjects met its primary endpoint and key secondary endpoints, with a favorable safety profile. The company plans to initiate Phase 3 trials. The lupus treatment market includes competing programs from UCB/Biogen, Cartesian Therapeutics, and Adicet Bio.Benzinga · Jan 6, 2026

AstraZeneca Prepares Showdown With JNJ, Amgen With Phase 3 Win For Myasthenia Gravis Drug CandidateAstraZeneca reported positive Phase 3 trial results for gefurulimab, a drug candidate treating generalized myasthenia gravis, demonstrating significant improvement in patient symptoms with no new safety concerns.Benzinga · Jul 24, 2025

Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateCartesian Therapeutics reported positive long-term results from its Phase 2b trial of Descartes-08 in myasthenia gravis, with plans to initiate a Phase 3 trial in Q2 2025. The company also expects to report preliminary data from a Phase 2 trial of Descartes-08 in systemic lupus erythematosus and initiate a Phase 2 pediatric basket trial in H2 2025. Cartesian had $182.1 million in cash as of March 31, 2025, expected to support operations into mid-2027.GlobeNewswire Inc. · May 8, 2025

US Stocks Futures Trade Mixed Ahead Of Opening Bell: 'Preserve Capital In Conditions Of High Uncertainty,' Says ExpertUS stock futures were volatile ahead of the market open, with experts advising investors to focus on capital preservation due to high uncertainty. The article discusses concerns over liquidity issues in the US banking system and the impact of tariffs on the markets.Benzinga · Apr 9, 2025

to start trading

RN

RNACCartesian Therapeutics, Inc. Common Stock

RNAC

Pay with—

Available Balance0.00

Your PositionYou don't own any RNAC yet.

Related Tickers

Earnings